ARTICLE IN PRESS

Diabetes & Metabolic Syndrome: Clinical Research & Reviews xxx (2017) xxx-xxx



Contents lists available at ScienceDirect

Diabetes & Metabolic Syndrome: Clinical Research & Reviews

journal homepage: www.elsevier.com/locate/dsx



Review

Vitamin supplements in type 2 diabetes mellitus management: A review

Mabel Kar-Wai Yan, Hanan Khalil*

School of Rural Health, Monash University, Victoria, Australia

ARTICLE INFO

Article history: Available online xxx

Keywords:
Diabetes mellitus
Type 2 diabetes
Vitamins
Management

ABSTRACT

Type 2 diabetes mellitus (T2DM) is a major public health challenge that affects countries across the world. The use of pharmacological therapy is often limited in some patients due to a loss of effect over time or development of adverse effects such as weight gain or hypoglycaemia. This has prompted searches into the role of non-pharmacological therapies in T2DM. The availability and use of vitamin supplements in developed countries have increased significantly and there is evidence that certain vitamins may have roles in the management of T2DM. This review examines the literature assessing the use of vitamins A, C, E, D, K and the B group vitamins (B1, B3, B7, B6, B9, B12) in the management of T2DM. No clear evidence supporting the beneficial role of any specific vitamin in the treatment of T2DM was found. Thus, it is recommended that until further studies are conducted to clarify the role of such vitamins in T2DM management, they should not be routinely recommended in clinical practice.

© 2017 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Contents

| 1. | Introduction | 00 | | | | |
|------------|---|----|--|--|--|--|
| 2. | Method | | | | | |
| 3. | Findings | 00 | | | | |
| | 3.1. Vitamin A | 00 | | | | |
| | 3.2. Antioxidant vitamins C, E | 00 | | | | |
| | 3.3. B-group vitamins (B1, B3, B7, B6/9/12) | 00 | | | | |
| | 3.3.1. Vitamin B1: thiamine | | | | | |
| | 3.3.2. Vitamin B3: niacin | 00 | | | | |
| | 3.3.3. Vitamin B7: biotin | 00 | | | | |
| | 3.3.4. Vitamin B6,9,12 | 00 | | | | |
| | 3.4. Vitamin D in T2DM | | | | | |
| | 3.5. Vitamin K | 00 | | | | |
| 4. | Implications for clinical practice | 00 | | | | |
| 5. | Conclusion | | | | | |
| | Conflicts of interest statement | 00 | | | | |
| | Role of funding source | 00 | | | | |
| | References | 00 | | | | |
| References | | | | | | |

1. Introduction

Type 2 diabetes mellitus (T2DM) is one of the greatest global public health challenges today with a steady increase in prevalence over the past three decades [1]. Management of T2DM involves the use of pharmacological agents such as oral hypoglycaemic drugs and insulin, which are effective in reducing glycaemic levels [2].

http://dx.doi.org/10.1016/j.dsx.2017.04.009

1871-4021/© 2017 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Please cite this article in press as: M.K.-W. Yan, H. Khalil, Vitamin supplements in type 2 diabetes mellitus management: A review, Diab Met Syndr: Clin Res Rev (2017), http://dx.doi.org/10.1016/j.dsx.2017.04.009

^{*} Corresponding author at: 1. Monash University, Faculty of Medicine, Nursing and Health Sciences, Monash Rural Health, MUDRH, Ollerton Rd., Moe, Vic 3825. 2. Centre for Chronic Diseases Management, a Joanna Briggs Centre of Excellence. E-mail address: hanan.khalil@monash.edu (H. Khalil).

ARTICLE IN PRESS

M.K.-W. Yan, H. Khalil/Diabetes & Metabolic Syndrome: Clinical Research & Reviews xxx (2017) xxx-xxx

Table 1 Summary of Results.

| Summary of Results. | | | | | | | |
|---|---|---|--|--|--|--|--|
| Study | Study Type | Participants | Intervention | Conclusion | | | |
| Vitamin A Brazionis et al. [14] | Cross-sectional study | 111 males aged 40–69 years with T2DM | Plasma concentration of carotenoid | Plasma carotenoid concentrations seem to be implicated in diabetic retinopathy, independent of established risk factors. | | | |
| Rhee and Plutzky [11] | Review | Patients with acne vulgaris | Isoretinoin | Further randomised-controlled trials are required to determine the effects or retinoid treatment on insulin sensitivity and metabolism in humans. | | | |
| Antioxidant Vi Montero et al. [21] | itamins C & E Systematic review | T2DM patients | Vitamin E and/or C supplementation | Supplementation with vitamin E and/or C has no effect on endothelial function in T2DM subjects. | | | |
| Afkhami- Ardekani et al. [22] | Randomised controlled trial | 84 T2DM patients | 500 mg or 1000 mg daily Vitamin C for 6 weeks | Consumption of 1000 mg supplementary vitamin C may be beneficial in decreasing blood glucose and lipids in patients with type 2 diabetes and thus reducing the risk of complications. | | | |
| Dakhale et al. [23] | Double-blinded randomised trial | 70 T2DM patients | Vitamin C 500 mg twice daily | Treatment with oral vitamin C with metformin was well tolerated and devoid of any side effects and associated with improved HbA_{1C} , making it a particularly attractive | | | |
| Siavash and Amini [24] | Randomised trial | 50 T2DM patients | Daily dose of 500 mg vitamin C for 3 month period | therapeutic adjuvant in treatment of T2DM. Vitamin C has similar effects to gemfibrozil on HDL- cholesterol, but no effects on other lipid concentrations | | | |
| Bhatt et al [25] | Open-label randomised trial | 62 T2DM patients | Daily dose 500 mg vitamin C for 3 month period | Supplementation with vitamin C resulted in a significant improvement in both total cholesterol and LDL cholesterol concentrations amongst the intervention | | | |
| Rajanandah et al. [27] | Randomised controlled trial | 92 patients with painful diabetic neuropathy | Vitamin E (400 IU) supplementation for 12 weeks | group. Supplementation of vitamin-E is effective in reducing some of the pain caused by diabetic neuropathy patients above 50 years of age. | | | |
| Suksomboon et al. [28] | Systematic review | T2DM patients | Vitamin E supplementation in doses up to 1800 IU/day | There is no beneficial effect of vitamin E supplementation in improving glycaemic control in | | | |
| Lonn et al. [29] | Randomised, double- blind, placebo- controlled trial | 9541 patients at high risk for cardiovascular events | Daily dose vitamin E (400 IU) | unselected patients with T2DM. Supplementation did not lower the incidence of cancer or major cardiovascular events. | | | |
| Shab-Bidar et al. [30] | Randomised controlled trial | 71 T2DM patients | Daily vitamin E supplementation (800 mg) for 2 months | There was no difference in serum fasting glucose levels, HbA_{1C} and beta-cell function found between the supplemented and non-supplemented groups. The use of pharmacological doses of vitamin E does not confer additional benefits and has little clinical significance. | | | |
| Vitamin B1 Rabbani et al. [36] | Randomised controlled trial (pilot study) | 40 T2DM patients | 300 mg/day thiamine supplementation | Thiamine supplements may have a role in the regression of urinary albumin excretion in diabetic nephropathy. | | | |
| Keogh et al. [37] | Randomised trial | 84 T2DM patients | High dose supplementation 300 mg/day | Increased thiamine supplementation may be required in T2DM patients commencing a weight-loss program. | | | |
| Vitamin B3: N AIM-HIGH trial [40] | liacin Randomised, multi- centre, prospective clinical trial | 3414 participants with established cardiovascular disease | Extended-release niacin added to intensive statin therapy with mean follow-up period 3 years | There is no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period amongst patients with atherosclerotic cardiovascular disease and LDL-C levels less than 70mg | | | |
| HPS2-THRIVE trial [41] | Randomised, double- blind, multicentre trial | 25,673 adults with vascular disease | $2\mathrm{g}$ extended release niacin and $40\mathrm{mg}$ laropiprant or placebo daily | per decilitre. Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious | | | |
| Pang et al. [42] | Randomised trial | T2DM patients on statin therapy | Adjunctive extended release niacin | adverse events ER niaicin therapy may provide cardiovascular disease risk benefits to patients with T2DM by increasing HDL concentrations. | | | |
| Vitamin B7: Bi Revilla- Monsalve et al. [47] | | 18 T2DM subjects; 15 non-diabetic subjects | Daily dose 61.4 µmol biotin or placebo for 28 days | Vitamin B7 significantly reduces plasma triacylglycerol and very-low-density-lipoprotein (VLDL) concentrations. | | | |
| Vitamin B6, B9 HOPE 2 Study [50] | | 5522 participants had vascular disease or diabetes | Daily administration of B- vitamin therapy (B9 2.5 mg, B6 50 mg, B12 1 mg) | Daily administration of the B-vitamin therapy reduced homocysteine concentrations by 25%, but no beneficial effects on major vascular events were observed except | | | |
| House et al. [52] | Multi-centre randomised double- | 238 participants with diabetic nephropathy | High-dose vitamin B supplement or placebo | for a significant reduction in the incidence of stroke. Among patients with diabetic nephropathy, high doses of B vitamins compared with placebo resulted in a greater decrease in GFR and an increase in vascular events. | | | |
| | | | | and the second seconds. | | | |

Please cite this article in press as: M.K.-W. Yan, H. Khalil, Vitamin supplements in type 2 diabetes mellitus management: A review, Diab Met Syndr: Clin Res Rev (2017), http://dx.doi.org/10.1016/j.dsx.2017.04.009

Download English Version:

https://daneshyari.com/en/article/8658863

Download Persian Version:

https://daneshyari.com/article/8658863

<u>Daneshyari.com</u>